Allergan Aesthetics received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve the appearance of the neck in adults over 21, expanding the product beyond its previously approved cheek indication. The approval broadens the product's commercial use and supports AbbVie's aesthetics portfolio. The news is positive but likely incremental rather than market-moving for the shares.
Allergan Aesthetics received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve the appearance of the neck in adults over 21, expanding the product beyond its previously approved cheek indication. The approval broadens the product's commercial use and supports AbbVie's aesthetics portfolio. The news is positive but likely incremental rather than market-moving for the shares.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
